Results 261 to 270 of about 209,402 (307)
Some of the next articles are maybe not open access.

Lipoproteins and Lipoprotein Metabolism

1975
The plasma lipoproteins provide the body with a transport system for the otherwise insoluble lipids. All lipids except for free fatty acids and lysolecithin, circulate in plasma from their site of origin to their site of utilization in association with these lipid-protein complexes, the lipoproteins. In healthy humans, more than 100 g of triglycerides,
S. Eisenberg, R. I. Levy
openaire   +2 more sources

Lipoprotein Apheresis

Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
openaire   +3 more sources

The Biochemistry of Lipoproteins

Journal of Inherited Metabolic Disease, 1988
SummaryLipids are transported in the blood in four major classes of lipoproteins. The triacylglycerol‐rich lipoproteins are chylomicrons and very‐low‐density lipoproteins (VLDL) which are produced by the small intestine and liver, respectively. These lipoproteins mainly carry fatty acids to adipose tissue and muscle where the triacylglycerol is ...
David N. Brindley, Andrew M. Salter
openaire   +3 more sources

Lipoprotein (a)

Baillière's Clinical Endocrinology and Metabolism, 1995
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
openaire   +2 more sources

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease

Journal of Clinical Lipidology, 2019
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M. Moriarty   +2 more
openaire   +3 more sources

Lipoprotein (a)

European Journal of Cardiovascular Prevention & Rehabilitation, 1994
Our understanding of the pathophysiological role of lipoprotein (a) in cardiovascular disease and its clinical importance has improved, but there are still gaps in our knowledge and analytical performance that hinder the appropriate management of patients.
openaire   +2 more sources

β-lipoprotein, lipoprotein lipase and atromid

Journal of Atherosclerosis Research, 1963
Summary The lipoprotein lipase activity eluted in connection with chromatographically separated β-lipoprotein was considerably lower in 6 cases of essential hyperlipaemia than the average for 7 healthy controls. Atromid administration seemed to increase the lipoprotein lipase activity per mg β-lipoprotein protein in 4 of 5 cases.
P. Bedding, B. Hood, B. Carlander
openaire   +3 more sources

Lipoprotein(a) : new insights into an atherogenic lipoprotein

The Clinical Investigator, 1994
Lipoprotein(a) constitutes a macromolecular complex in human plasma that combines structural features from the blood clotting and the lipoprotein systems. Aside from the discovery of lipoprotein(a) [Lp(a)] as a potential independent risk factor for premature cardiovascular disease its physiological role and activity remains obscure.
Bartens, Werner, Wanner, Christoph
openaire   +3 more sources

Lipoprotein(a)

JAMA
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
openaire   +2 more sources

Lipoprotein(a) and atherogenesis

Trends in Cardiovascular Medicine, 1994
Lipoprotein(a) is a major inherited risk factor for atherosclerosis. Many of its activities depend on its plasminlike component, apolipoprotein(a). In vitro studies suggest that apolipoprotein(a) could enhance lipid deposition through binding to sites in the vessel wall, interfere with fibrinolysis, and modulate smooth muscle cell activity.
Richard M. Lawn, Alexander C. Liu
openaire   +3 more sources

Home - About - Disclaimer - Privacy